West Leyden High School senior awaiting heart transplant graduates at Lurie Children's Hospital
Except, the party was held on the 22nd floor of Lurie Children's Hospital in honor of one of the hospital's patients: 18-year-old Taevion Norris. He had been attending West Leyden High School in Northlake when his senior year was suddenly interrupted in March due to heart failure, forcing him to spend the tail end of his final year of high school in the hospital.
But Norris refused to let his condition stop him from graduating on time — and succeeded. On Wednesday, Norris — wearing a blue cap and gown — was handed his diploma. Graduation music played in the background as he traversed from one end of the hospital hallway into the room of the ceremony.
'This is a very good day. Despite what he's going through, he was still able to graduate with his class,' Tainica Norris, Taevion's mother, said. 'It's good that he has a big crowd to see him achieve and accomplish one of his dreams and his goals, and just to be loved by everybody, because nobody knows what it's like to face what he has.'
In 2019, her eldest son was diagnosed with Duchenne muscular dystrophy, a neuromuscular condition where the body is unable to make dystrophin — a protein that helps keep muscles together. Without dystrophin, muscles in various parts of the body — such as the legs, arms and heart — get replaced with fibrous tissue. That can lead to bigger health issues, such as heart failure and losing the ability to walk.
Norris was in elementary school when one day, his mother received a phone call from the gym teacher.
'I was at work and he told me that I needed to get Taevion tested,' she recalled. 'And I'm like, 'What's going on?' He was like, 'I noticed that Taevion is not moving like he used to move, like his pace has slowed down.''
Norris was eventually referred to Dr. Katheryn Gambetta, a pediatric cardiologist at Lurie Children's Hospital. Gambetta said that Norris 'was around 12 or 13' when he was diagnosed and said that he was 'coming in at least every six months.'
'But he actually had heart dysfunction, probably when he was around 15, and then over time, that just got worse and worse,' Gambetta said. 'This is what we see — that heart dysfunction gets worse over time in boys and that the leading cause of death in boys who have Duchenne muscular dystrophy is due to heart failure.'
In the past year, Norris — who uses a wheelchair — had been admitted to the hospital multiple times, but his admittance about two months ago was unlike any of the others.
'Two months ago, he got really, really sick. He wasn't sleeping, he wasn't eating, he was just throwing up,' his mother recalled.
One morning, around 3 a.m., Norris called his mom and she found vomit everywhere in the bathroom, prompting her to call the ambulance. On March 11, Norris was admitted as an inpatient to the hospital, which he was not happy about.
'And he said, 'Mama, see I told you I didn't want to come here because I knew they were gonna keep me here. I want to go back to school,'' his mother said. 'I said, 'Taevion, it's either that or you're not gonna be here.''
The journey to get her son to graduation has not been an easy one.
'I stopped working because it started getting tough,' Norris' mother said. 'Kept going to the doctor, he kept getting more sicker, missing a lot of school, calling the school, let them know what's going on. It's just been hard.'
Norris' mother initially did not think that her son would be able to graduate on time while in the hospital. 'I thought it was gonna be a struggle, but he proved me wrong,' she said.
While it was not the first time Lurie Children's Hospital had a graduation for a student, the level of care from West Leyden High School that was put into helping Norris graduate was noted by the staff at Lurie Children's Hospital, making this one feel extra special.
Hana Herrick, a school services coordinator for Lurie Children's Hospital, said that she started working with Norris when he was admitted about two and a half months ago.
'Taevion can be very stoic at times, and he is very shy,' Herrick said. Finishing up school for Norris looked like a hybrid model, where he would have online classes with an instructor from his high school and Herrick by his side for additional in-person support.
Providing those online classes, Herrick said, was 'out of the norm.'
'Most schools don't do that for their students, so that was awesome,' Herrick said.
One of Herrick's favorite moments with him was when she told him that he had one task left, which was around the same time the two started working together: tackle George Orwell's novel 'Animal Farm.'
'The smile that came across his face was just so memorable,' Herrick said. 'And he was like, 'Whoa, really.' Like he couldn't believe it.'
Herrick said she was worried initially about how Norris was going to perceive the book, but those worries soon faded into the background. Not only did Norris finish reading the whole book, but he watched both movie adaptations and came up with rigorous reading comprehension questions.
As for next steps, Norris is on a waiting list for a heart transplant. According to Gambetta, he's been on the list for a heart transplant since May 1. Gambetta said she is hopeful that Norris will get his heart transplant soon, noting that he's been given an Impella ventricular assist device to allow him time to get a transplant. His family is also fundraising for a minivan through the Jett Foundation in order to make traveling together as a family easier.
Beyond the heart transplant, what career path Norris will pick is still up in the air, but his mother did note that he had previously considered being an NBA commentator.
'He wanted to be that. So I said, 'OK, well, you're gonna have to work for it. You're gonna have to learn how to do what they do and say what they say, and learn how to dress — well, he knows how to dress himself,' his mother said. 'So hopefully that might still be his pathway.'
But regardless of his journey, one thing was made clear as he was handed his diploma by Nick Polyak, superintendent of Leyden High School District 212.
'No matter where you go and what you do, you will always be a Leyden Eagle,' Polyak said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Buzz Feed
4 hours ago
- Buzz Feed
20 Foods Americans Say Should Never Be Banned
Everyone has a favorite food, but some people have a food they love so intensely that they'd start a revolution if it were ever banned, and with Health and Human Services Secretary Robert F. Kennedy Jr.'s continuous crackdowns on the nation's food supply, the possibility seems ever more realistic. I was curious about what foods people could never give up, so I asked Tasty readers about the snacks that would make them march the streets in protest if they were ever banned. Let's just say there were some very passionate answers. Here are 20 different foods that would surely cause people to revolt if they were forbidden, as told by their most loyal fans: "Lay's potato chips are my life. The crunchy yet thin chip and the salty goodness are so amazing that no other chip can compete. If it were banned, I think I would just cry. It's my favorite snack and is a staple in my house." —Esti, 25, New York "Krispy Kreme donuts!" "Oreos. You can pry my black-and-white circles of deliciousness from my cold, dead hands." —Sonia, 25, Massachusetts "The BUILT Puff Protein Bars are my favorite snack, and it's like eating a giant chocolate-coated marshmallow. If the FDA banned them, I would literally petition and protest all I could in front of them until I could eat them and buy them again." "Smartfood White Cheddar Popcorn. It was a big staple of my childhood, and I would hate to see it go." —Matilda, 25, Oregon "Bacon. Specifically, American-style bacon (I like Canadian bacon, but I could survive without it). If they try to ban it, there will be rioting in the streets." "I would be so sad if they got rid of those really terrible, super soft cookies with the half-inch of icing on top of them. I don't buy them often, but sometimes that craving hits hard." —Allie, 36, Arizona "Mint Milanos." "Annie's Mac 'n' Cheese, as childish as it is. It's always been my American staple, and I would hate to see it banned in the US." —Anonymous "I think that if the US banned Gushers, I would start hyperventilating." Want to cook recipes in step-by-step mode right from your phone? Download the free Tasty app right now. "Animal Crackers." —Leanna, 13, Michigan "Reese's Peanut Butter Cups." "Diet Coke." —silverdreamer30 "Gummy Bears and Watermelon Sour Patch Kids — the best candies ever!" "Nutella!!!!!" —fedora-the-explora "Doritos, specifically Nacho Cheese and Cool Ranch." "Goldfish." —Khylah "Blue Raspberry is the superior candy/slushie/Slurpee flavor. I would be DEVASTATED if that got taken away." "Starbursts." —littlemintmunchin "UnMeat Luncheon vegan meat. It is not my favorite food, but it is the junkiest, most trashy food I eat. It is absolutely not good for me, but I enjoy it once in a while, and I will not feel guilty. Unpopular opinion: It tastes better than SPAM." Do you have a favorite food that belongs on this list? Let me know in the comments! You know what we'll never ban? Tasty recipes! So download our free app to browse and save everything from 30-minute meals to show-stopping desserts — no subscription required.


Business Wire
4 hours ago
- Business Wire
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). 'Receipt of Orphan Drug Designation from the FDA for PBGENE-DMD underscores the tremendous unmet need and urgency to deliver safe treatments that significantly improve muscle function over time for boys living with Duchenne muscular dystrophy,' said Cindy Atwell, Chief Development and Business Officer at Precision BioSciences. 'This regulatory milestone builds on our recent receipt of Rare Pediatric Disease designation and, together with our preclinical body of evidence, gives us tremendous confidence as we move this program towards the clinic. Looking ahead, we remain in active dialogue with the FDA as we advance PBGENE-DMD toward regulatory milestones, with clinical data anticipated in 2026.' The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides sponsors certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for that use. About PBGENE-DMD PBGENE-DMD is Precision's development program for the treatment of DMD. The approach uses two complementary ARCUS nucleases delivered via a one-time administration in a single AAV to excise exons 45-55 of the dystrophin gene with the aim of restoring near full-length dystrophin protein within the body to improve functional outcomes. PBGENE-DMD is intended to address up to 60% of the DMD patient population. In preclinical studies, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and produced significant, durable functional improvements in a humanized DMD mouse model. PBGENE-DMD restored the body's ability to produce a near full-length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement. PBGENE-DMD was recently granted FDA Rare Pediatric Disease (RPD) designation for the treatment of DMD. The Company is advancing the final IND-enabling toxicology studies and is working closely with leading DMD clinicians to design a first in human trial optimized for safety and efficacy. Clinical grade material is in preparation, with initial clinical data expected in 2026. About Precision BioSciences, Inc. Precision's two lead programs, PBGENE-HBV, for chronic Hepatitis B, and PBGENE-DMD, for Duchenne muscular dystrophy, are focused on areas with large patient populations with high unmet need. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline prioritizes in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our and our partners' and licensees' product candidates and gene editing approaches; the potential of PBGENE-DMD to safely drive meaningful improvement in functional and durable benefit over time for up to 60% of patients with DMD; the design on PBGENE-DMD to permanently edit a patient's own DNA sequence, resulting in naturally-produced, near full-length dystrophin protein proven known to be functional in humans; the benefits of an Orphan Drug Designation including financial incentives and regulatory exclusivity; the potential value of a Priority Review Voucher(if awarded) including priority review for a different product or sale to another sponsor; the expected timing of regulatory processes and clinical operations (including IND and/or CTA filings, studies, enrollment and clinical data for PBGENE-DMD; and anticipated timing of clinical data. In some cases, you can identify forward-looking statements by terms such as 'aim,' 'anticipate,' 'appear,' 'approach,' 'believe,' , 'confidence', 'contemplate,' 'could,' 'design' 'designed,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look,' 'may,' 'mission,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'pursue,' 'should,' 'strive,' 'suggest,' 'target,' 'will,' 'would,' or the negative thereof and similar words and expressions. Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim 'top-line' and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at and the Investors page of our website under SEC Filings at All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.


Bloomberg
18 hours ago
- Bloomberg
Roche Pauses Shipments of Contested Gene Therapy Outside the US
Roche Holding AG paused all shipments of the controversial gene therapy Elevidys following a similar action by the embattled US biotechnology company that developed the treatment. The Swiss drugmaker said the pause effective today applies to new orders of Elevidys in countries outside the U.S. that base their approvals off Food and Drug Administration decisions. It covers all patients with Duchenne muscular dystrophy regardless of their ability to walk. It's voluntary and temporary, the company said in an emailed statement.